New
Our co-authored paper titled Emerging drugs for the treatment of vitiligo has been published in the journal Expert Opinion on Emerging Drugs.
This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant and repigmenting mechanisms, basic fibroblast growth factors, afamelanotide and targeted immunotherapy.
For more information about emerging treatments for vitiligo, check out Drug Pipelines or Trials Hub sections of our website.
We also recommend reading our exclusive Vitiligo Drug Pipeline Analysis and Market Insights.
FAQOther Questions
- Can chemicals cause vitiligo?
Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.